Subscribe to Search results

The record of the 27 November meeting of the Working Group on AIDS described it as having gone "reasonable [sic] well"; whereas other reports expressed a significantly different viewpoint.

Published on:

Dr Harris said of heat treatment of Factor VIII in a meeting of the Working Group on AIDS that: "although there is not yet the evidence to guarantee that this is satisfactory; the view was nevertheless unanimous that it should be done."

Published on:

Professor Bloom issued a questionnaire to haemophilia centre directors. It asked whether (and to what extent) they were still using non-heat-treated product. At a meeting of the AIDS group of UKHCDO directors his analysis was discussed.

Published on:

Dr Harris of Armour described Dr Rotblat as "a valuable ally at the moment" and recorded that "I am now obliged to report Dr Whitmore's patient who sero-converted following treatment with Factorate HT Y69402 to her as Dr Whitmore has confirmed that the patient remains HTLV-III positive."

Published on:

A report prepared by Dr Rotblat for the CMO repeated Armour's claim that they had done viral inactivation studies "and shown good inactivation".

Published on:

Dr Rotblat contacted the companies manufacturing Factor 8 concentrates to draw together information for the CMO regarding their viral inactivation processes.

Published on:

Dr Smithies' communication did not suggest any specific knowledge regarding the Armour product or the Lewisham patient.

Published on:

Dr Smithies informed the CMO that she had been told by Dr Dale Lawrence of the CDC that he was seeking a sample of blood from the Lewisham patient.

Published on:

In a note from Dr Smithies to Dr Godber, she informed him that the CBLA had announced that they planned to heat all Factor 8 manufactured at BPL/PFL from April 1985.

Published on:

An internal DHSS minute, referring to Armour's letter to haemophilia centre directors withdrawing batches of Factorate which had not been donor screened, stated that Rorer Health Care Ltd claimed to be in compliance with their product licence and that the matter had not been treated as a product defect.

Published on:

A memo from Dr Harris to Dr Smithies attached a letter that was sent to all haemophilia centre directors confirming the availability of heated Factor 8 concentrates and advising that there was therefore no longer any need to use un-heat-treated Factor VIII concentrate.

Published on:

In a memo from Dr Walford to Dr Fowler, Dr Walford flagged that Travenol (Hyland) were planning a symposium in early 1983 to launch a reduced hepatitis risk product.

Published on:

In a minute from D O Hagger to Mr O'Connor, it was decided that, in light of recent seroconversion cases, if Armour did not agree to a voluntary withdrawal the DHSS would need to consider the case further as to what their course of action should be.

Published on:

Dr Hill, of Birmingham Children's Hospital, wrote to the Department of Health stating his belief that there had been three definite cases and one probable case of seroconversion amongst his patients.

Published on:

In a memo from Dr Isaacs to Dr Rotblat, Dr Isaacs attached a letter received from Peter Jones in which he suggested taking action against the Armour material.

Published on:

An editorial in the "British Medical Journal" asserted that the protein fractionation centres lacked sufficient staff, accommodation, equipment and the basic organisational units to do the job.

Published on:

In a letter from Dr Biggs to Dr Godber, she called attention to the lack of organisation, apparatus and buildings needed in order to produce Factor 8.

Published on:

In the minutes of an AIDS group of haemophilia centre directors' meeting, Dr Mortimer told the meeting that he was concerned to see that a large number of centres were still using non-heat-treated Factor 8, and suggested that all directors should be advised not to use it.

Published on:

During a meeting of the AIDS group of haemophilia centre directors, directors were recommended to use only heat-treated products now these were available.

Published on:

At a UKHCDO Hepatitis Working Party meeting Dr Craske identified eight patients treated with (unheated) Factor 9 who had seroconverted.

Published on: